RTI Biologics Earnings: Here’s Why Investors Like These Results

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

RTI Biologics, Inc. (NASDAQ:RTIX) delivered a profit and met Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 6.46%.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

RTI Biologics, Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share decreased 50% to $0.02 in the quarter versus EPS of $0.04 in the year-earlier quarter.

Revenue: Decreased 7.64% to $40.4 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: RTI Biologics, Inc. reported adjusted EPS income of $0.02 per share. By that measure, the company met the mean analyst estimate of $0.02. It beat the average revenue estimate of $38.76 million.

Quoting Management: “Our first quarter results were in line with our expectations,” said Brian K. Hutchison, president and chief executive officer of RTI. “In a very challenging environment, our distribution team has worked hard to respond to customer reaction to the FDA warning letter that was received in October 2012. International revenues continued to be negatively impacted by inaccuracies in European media coverage about the company and the tissue industry. We will continue to diligently work through these issues until we bring them to resolution.”

Key Stats (on next page)…

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business